바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.76 No.6
Citation Share

Effectiveness of Smoking Cessation Using Motivational Interviewing in Patients Consulting a Pulmonologist

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2014, v.76 no.6, pp.276-283






& (2014). Effectiveness of Smoking Cessation Using Motivational Interviewing in Patients Consulting a Pulmonologist. Tuberculosis & Respiratory Diseases, 76(6), 276-283.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: We aimed to investigate the role of the physician in practice and the factors that influence the success rate of smoking cessation. Methods: This study retrospectively analyzed 126 adult smokers who had visited the outpatient department of pulmonology, and received motivational interviewing with or without supplement drugs. The findings include continuous smoking abstinence rate, which was evaluated at 6, 12 and 24 weeks, and the factors associated with continuous abstinence for 6 months or longer. Results: The patients with only motivational interviewing accounted for 57.9%, while the nicotine patch therapy was applied to 30.2%; and varenicline was prescribed to 11.9%. The smoking cessation success rates of at 6, 12, and 24 weeks were 55.6%, 47.6%, and 33.3%, respectively. However, even in the failure group at six months, tobacco consumption was decreased under 10 cigarettes per day in 42.1% (53/126). In multivariate logistic regression analysis, degree of Fagerstöm Test for Nicotine Dependence (p=0.034; odds ratio, 3.607; 95% confidence interval [CI], 1.102–1.807), the absence of smoking-related lung disease (p=0.008; odds ratio, 4.693; 95% CI, 1.497–14.707), and education level (p=0.001; odds ratio, 181.420; 95% CI, 8.414–3,911.502) were the predictors of successful smoking cessation. Conclusion: An improved continuous smoking abstinence rate can be obtained by motivational interviewing, regardless of the association with pharmacotherapy.

keywords
Smoking Cessation, Tabacco Dependence, Motivational Interviewing

Reference

1.

1. Tonnesen P, Carrozzi L, Fagerstrom KO, Gratziou C, Jimenez-Ruiz C, Nardini S, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007;29:390-417.

2.

2. Ministry of Health and Welfare. Korea National Health and Nutrition Examination Survey (KNHANES V-3). Seoul: Korea Centers for Disease Control and Prevention; 2012.

3.

3. Lee JY, Kim MJ, Jun HJ, Kang M, Park AR, Oh DE, et al. Adherence to varenicline and abstinence rates for quitting smoking in a private health promotion center-based smoking cessation clinic. Tuberc Respir Dis 2012;72:426-32.

4.

4. Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2013;5:CD000165.

5.

5. Jeon K, Song JU, Um SW, Koh WJ, Suh GY, Chung MP, et al. Bronchoscopic findings of pulmonary paragonimiasis. Tuberc Respir Dis 2009;67:512-6.

6.

6. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991;86:1119-27.

7.

7. Perez-Rios M, Santiago-Perez MI, Alonso B, Malvar A, Hervada X, de Leon J. Fagerstrom test for nicotine dependence vs heavy smoking index in a general population survey. BMC Public Health 2009;9:493.

8.

8. Myung SK, Seo HG, Park S, Kim Y, Kim DJ, Lee DH, et al. Sociodemographic and smoking behavioral predictors associated with smoking cessation according to follow-up periods:a randomized, double-blind, placebo-controlled trial of transdermal nicotine patches. J Korean Med Sci 2007;22:1065-70.

9.

9. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-56.

10.

10. Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29:1027-39.

11.

11. Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009;14:384-92.

12.

12. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004;99:29-38.

13.

13. Catley D, Harris KJ, Goggin K, Richter K, Williams K, Patten C, et al. Motivational Interviewing for encouraging quit attempts among unmotivated smokers: study protocol of a randomized, controlled, efficacy trial. BMC Public Health 2012;12:456.

14.

14. Noordman J. Lifestyle counseling by physicians and practice nurses in primary care: an analysis of daily practice. Utrecht:Netherlands Institute for Health Services Research; 2013.

15.

15. Martins RK, McNeil DW. Review of motivational interviewing in promoting health behaviors. Clin Psychol Rev 2009;29:283-93.

16.

16. Ojedokun J, Keane S, O’Connor K. Lung age bio-feedback using a portable lung age meter with brief advice during routine consultations promote smoking cessation? Know2quit multicenter randomized control trial. J Gen Pract 2013;1:123.

17.

17. Borland R, Balmford J, Swift E. Effects of timing of initiation and planning on smoking cessation outcomes: study protocol for a randomised controlled trial. BMC Public Health 2013;13:235.

18.

18. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000;55:987-99.

19.

19. Lancaster T, Stead L. Extended-duration transdermal nicotine therapy was more effective than standard-duration therapy for smoking cessation. Ann Intern Med 2010;152:JC4-8.

20.

20. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. BMJ 1994;309:842-6.

21.

21. Yeo CD, Kang HH, Kang JY, Kim SK, Kim MS, Kim SS, et al. A short-term effectiveness of smoking cessation intervention in outpatient department of pulmonology. Tuberc Respir Dis 2011;71:114-9.

22.

22. Balmford J, Leifert JA, Schulz C, Elze M, Jaehne A. Implementation and effectiveness of a hospital smoking cessation service in Germany. Patient Educ Couns 2014;94:103-9.

23.

23. Raupach T, Brown J, Herbec A, Brose L, West R. A systematic review of studies assessing the association between adherence to smoking cessation medication and treatment success. Addiction 2014;109:35-43.

24.

24. Shah SD, Wilken LA, Winkler SR, Lin SJ. Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc (2003) 2008;48:659-65.

25.

25. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001;357:1571-5.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy